This is out Library. Please click on the article title to view the details.
submitted by: admin on 05/08/2015
Dr. Gracer reviews cutting edge pharmaceutical, nutritional, and emotional approaches to dealing with addictions to alcohol and drugs. The strategies presented are a breakthrough to a new level of excellence in treating addictions.
submitted by: admin on 03/21/2023
Whenever a new technology is invented, if it is good it will displace the old. This can have profound economic consequences that are abhorent to business-minded corporations. Conflicts of interest with the FDA are discussed.
submitted by: admin on 06/24/2016
Lithocholic acid (LCA) is a liver bile acid that has the ability to selectively kill cancer cells while not affecting normal cells. It works by causing cancer cell mitochondria to self-destruct. LCA also activates the vitamin D receptor site. It prevents whole tumor growth and slows down the development of metastases. In tests it has been shown to...
submitted by: admin on 10/09/2013
Every year there are advances in research that should be brought forward into clinical practice but don't make it because of conflicts of interest. One reason is that new technologies may require more study or financial investment by the practitioner. Second, new technologies will replace old ones that are profitable. The example of the photon stimulator...
submitted by: admin on 10/12/2013
The first step in considering treatment is to make an accurate diagnosis. The body heals itself and we need to support it to promote healing by looking at a wide range of therapies that range from nutrition to surgery. Lifestyle medicine is the first place to start. Having flexibility in choosing a treatment is key to finding the best treatment.
submitted by: admin on 02/19/2015
Pradaxa is currently the only FDA approved drug that inhibits factor Xa and seems to have significant advantages over Coumadin. Early studies have shown a 21% less likely risk of stroke in atrial fibrillation, a 31% lower risk of bleeding, and an 11% lower mortality rate. Two drugs under study by the FDA now include Xarelto, and Eliquis.